Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Servier
Ricoh USA, Inc.
Var2 Pharmaceuticals
IGM Biosciences, Inc.
Taproot Health
TopAlliance Biosciences
EpicentRx, Inc.
Ipsen
Tracon Pharmaceuticals Inc.
Power Life Sciences Inc.
Emerald Clinical Inc.
Genentech, Inc.
Celgene
AEterna Zentaris
Novartis
Celldex Therapeutics
Valerio Therapeutics
Valerio Therapeutics
INSYS Therapeutics Inc
Infinity Pharmaceuticals, Inc.